Spots Global Cancer Trial Database for nimotuzumab
Every month we try and update this database with for nimotuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC | NCT03557112 | Nasopharyngeal ... | Nimotuzumab Cisplatin | 18 Years - 70 Years | Guiyang Medical University | |
| Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | NCT05316480 | Pancreatic Neur... | Nimotuzumab | 18 Years - 80 Years | Fudan University | |
| Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers | NCT01382745 | Squamous Cell C... | Nimotuzumab Intensity Modul... | 18 Years - | Sir Mortimer B. Davis - Jewish General Hospital | |
| Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer | NCT02591784 | Esophageal | Nimotuzumab Radiotherapy | 18 Years - 75 Years | Biotech Pharmaceutical Co., Ltd. | |
| Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial | NCT01463605 | Esophageal Canc... | Nimotuzumab | 70 Years - | ChineseAMS | |
| Single-arm Study of Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer | NCT06389760 | Pancreatic Canc... | Nimotuzumab mFOLFIRINOX | 18 Years - 70 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Nimotuzumab in Adults With Glioblastoma Multiforma | NCT00753246 | Adults With Gli... | nimotuzumab | 18 Years - 70 Years | Oncoscience AG | |
| Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors | NCT02395068 | Solid Tumors | Nimotuzumab irinotecan | 18 Years - 70 Years | Biotech Pharmaceutical Co., Ltd. | |
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | NCT04532229 | Diffuse Intrins... | Nimotuzumab+CRT... | 3 Years - 15 Years | Biotech Pharmaceutical Co., Ltd. | |
| Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma | NCT02858206 | Esophageal Neop... | IMRT simultaneo... Nimotuzumab Paclitaxel Nedaplatin Esophagectomy | 18 Years - 69 Years | ChineseAMS | |
| Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer | NCT02039791 | Cervical Cancer | Nimotuzumab Carboplatin Paclitaxel | 18 Years - 70 Years | Biotech Pharmaceutical Co., Ltd. | |
| Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy | NCT01402180 | Esophageal Squa... | Nimotuzumab Radiation thera... radiation thera... chemotherapy chemotherapy | 18 Years - 75 Years | Fudan University | |
| Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | NCT02272699 | Esophageal Squa... | Nimotuzumab Paclitaxel Cisplatin Radiation Surgery | 18 Years - 65 Years | Peking University | |
| Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | NCT02272699 | Esophageal Squa... | Nimotuzumab Paclitaxel Cisplatin Radiation Surgery | 18 Years - 65 Years | Peking University | |
| TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | NCT04475016 | Penile Cancer | Albumin-Bound P... Ifosfamide Cisplatin Nimotuzumab Triprilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | NCT06429904 | Locally Advance... | Nimotuzumab+ NA... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma | NCT02370849 | Stomach Neoplas... | nimotuzumab cisplatin S-1 | 18 Years - | ChineseAMS | |
| Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer | NCT01899118 | Locally Advance... | Preoperative ir... Nimotuzumab Oxaliplatin Capecitabine | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | NCT06429904 | Locally Advance... | Nimotuzumab+ NA... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | NCT03666221 | Recurrent Nasop... | Nimotuzumab | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma. | NCT01993784 | Esophageal Squa... | nimotuzumab | 18 Years - 75 Years | Peking University | |
| Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery | NCT05024019 | Head and Neck S... | Nimotuzumab | 18 Years - | Eye & ENT Hospital of Fudan University | |
| Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery | NCT04459065 | Lung Cancer | IRDye800CW-nimo... | 18 Years - 80 Years | University of Saskatchewan | |
| Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer | NCT01516996 | Oropharyngeal C... Hypopharyngeal ... | docetaxel and c... IMRT Nimotuzumab | 18 Years - 70 Years | The Second People's Hospital of Sichuan | |
| Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer | NCT01180166 | Gastric Cancer Concurrent Chem... | nimotuzumab | 18 Years - 75 Years | ChineseAMS | |
| Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells | NCT03554889 | Advanced Cancer ADCC NK Cell Mediate... Nimotuzumab Adaptive Transf... | NK Cell adaptiv... Nimotuzumab | 18 Years - 75 Years | Hangzhou Cancer Hospital | |
| Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer | NCT00983047 | Advanced Non-Sm... | Nimotuzumab and... | 18 Years - 75 Years | Biotech Pharmaceutical Co., Ltd. | |
| Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer | NCT00702481 | Head and Neck C... | Nimotuzumab Cisplatin Radiation | 21 Years - 70 Years | National Cancer Centre, Singapore | |
| Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer | NCT00985998 | Non-small Cell ... | Nimotuzumab and... | 18 Years - 65 Years | Biotech Pharmaceutical Co., Ltd. | |
| Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | NCT06409429 | Pancreatic Canc... | Nimotuzumab GX Placebo | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC | NCT02012062 | Nasopharyngeal ... | TPF neoadjuvant... Concurrent chem... Concurrent nimo... Radical radioth... | 18 Years - 70 Years | Fudan University | |
| Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | NCT06048913 | Esophageal Carc... | Nimotuzumab Tigio Concurrent radi... | 70 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer | NCT01516996 | Oropharyngeal C... Hypopharyngeal ... | docetaxel and c... IMRT Nimotuzumab | 18 Years - 70 Years | The Second People's Hospital of Sichuan | |
| Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients | NCT06429839 | Esophageal Canc... Nimotuzumab Chemoradiothera... Chemotherapy Immunotherapy | Nimotuzumab wit... | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma | NCT02370849 | Stomach Neoplas... | nimotuzumab cisplatin S-1 | 18 Years - | ChineseAMS | |
| TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | NCT04475016 | Penile Cancer | Albumin-Bound P... Ifosfamide Cisplatin Nimotuzumab Triprilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer | NCT01938105 | Locally Advance... | Nimotuzumab+che... | 18 Years - 75 Years | People's Hospital of Guangxi | |
| Nimotuzumab in Children With Intrinsic Pontine Glioma | NCT00561691 | Diffuse Instrin... | nimotuzumab | 3 Years - 20 Years | Oncoscience AG | |
| Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer | NCT00493857 | Colorectal Canc... | Nimotuzumab Hum... Nimotuzumab | 18 Years - | YM BioSciences | |
| Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC | NCT02012062 | Nasopharyngeal ... | TPF neoadjuvant... Concurrent chem... Concurrent nimo... Radical radioth... | 18 Years - 70 Years | Fudan University | |
| Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma | NCT06410651 | Esophageal Canc... Nimotuzumab Chemoradiothera... Chemotherapy Immunotherapy | Nimotuzumab wit... | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma | NCT04976478 | Cervical Squamo... | Nimotuzumab EBRT combined w... | 65 Years - | Peking University Third Hospital | |
| Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | NCT01813253 | Gastric Cancer Gastroesophagea... | Irinotecan Nimotuzumab | 20 Years - | Kuhnil Pharmaceutical Co., Ltd. | |
| Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | NCT03915132 | Nasopharyngeal ... | Nimotuzumab VMAT | 70 Years - | ChineseAMS | |
| Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells | NCT03554889 | Advanced Cancer ADCC NK Cell Mediate... Nimotuzumab Adaptive Transf... | NK Cell adaptiv... Nimotuzumab | 18 Years - 75 Years | Hangzhou Cancer Hospital | |
| Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery | NCT05024019 | Head and Neck S... | Nimotuzumab | 18 Years - | Eye & ENT Hospital of Fudan University | |
| Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma | NCT02611700 | Esophageal Squa... | Nimotuzumab Paclitaxel Cisplatin Placebo | 18 Years - | Biotech Pharmaceutical Co., Ltd. | |
| A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer | NCT01249352 | Esophageal Canc... Adenocarcinoma | Nimotuzumab Cisplatin Fluorouracil Radiotherapy | 18 Years - | Eurofarma Laboratorios S.A. | |
| Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis | NCT06405685 | Pancreatic Canc... | Nimotuzumab AG | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma | NCT01688700 | Esophageal Squa... | Nimotuzumab com... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | NCT03025958 | Nasopharyngeal ... | Nimotuzumab Radiation | 65 Years - | Zhejiang Cancer Hospital | |
| Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma | NCT01145170 | Diffuse Intrins... | Radiotherapy Nimotuzumab | 3 Years - 18 Years | Eurofarma Laboratorios S.A. | |
| Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | NCT06429904 | Locally Advance... | Nimotuzumab+ NA... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Nimotuzumab in Adults With Pancreatic Cancer | NCT00561990 | Pancreatic Canc... | Nimotuzumab | 18 Years - 100 Years | Oncoscience AG | |
| Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children | NCT02672241 | Childhood Brain... | Nimotuzumab Temozolomide | 3 Years - 12 Years | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer | NCT02705612 | Cervical Cancer | Cisplatin External Beam R... Internal Radiat... nimotuzumab | 18 Years - 70 Years | Air Force Military Medical University, China | |
| Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure | NCT06413017 | HCC | Nimotuzumab ICIs(Immune che... | 17 Years - 79 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients | NCT01393080 | Non-small Cell ... | Nimotuzumab and... TP regimen | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Neoadjuvant Chemoradiotherapy Combined With Camrelizumab and Nimotuzumab for Esophageal Squamous Cell Carcinoma | NCT05355168 | Toxicity, Drug | neoadjuvant che... | 18 Years - 75 Years | Anhui Provincial Hospital | |
| Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study | NCT06404840 | Pancreatic Canc... | nimotuzumab AG chemotherapy | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer | NCT01336049 | Esophageal Squa... | Nimotuzumab | 18 Years - 75 Years | Peking University | |
| Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | NCT03388372 | Glioblastoma | Nimotuzumab Temozolomide Radiotherapy | 18 Years - 75 Years | Biotech Pharmaceutical Co., Ltd. | |
| Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT00910117 | Head and Neck C... | nimotuzumab PF regimen (cis... | 18 Years - 70 Years | Fudan University | |
| Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer | NCT04821778 | Esophagus Cance... Esophagogastric... Chemoradiation Targeted Therap... Immunotherapy Chemotherapy Ef... | Radiotherapy Platinum based ... Paclitaxel base... Immunotherapy 5-FU Analog bas... Nimotuzumab | 18 Years - | ChineseAMS | |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma | NCT04664244 | Recurrent Cervi... Radiotherapy Epidermal Growt... Nimotuzumab Objective Respo... Progression-fre... Overall Surviva... | Combination of ... | 18 Years - | Peking Union Medical College Hospital | |
| Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | NCT03666221 | Recurrent Nasop... | Nimotuzumab | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma | NCT03400592 | Stomach Neoplas... | Irinotecan nimotuzumab | 18 Years - 80 Years | Peking University | |
| A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer | NCT00369447 | Non-small-cell ... | External radiot... nimotuzumab | 18 Years - | YM BioSciences | |
| A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma | NCT04367909 | Oral Squamous C... | Nimotuzumab Docetaxel Carboplatin | 18 Years - 75 Years | China Three Gorges University, Yichang, China | |
| Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer | NCT01336049 | Esophageal Squa... | Nimotuzumab | 18 Years - 75 Years | Peking University | |
| A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases | NCT00872482 | Metastatic Non-... | nimotuzumab | 18 Years - | YM BioSciences | |
| Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma | NCT02858206 | Esophageal Neop... | IMRT simultaneo... Nimotuzumab Paclitaxel Nedaplatin Esophagectomy | 18 Years - 69 Years | ChineseAMS | |
| Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma | NCT02428764 | Lung Cancer | Nimotuzumab Gemcitabine Carboplatin Surgery | 18 Years - 75 Years | Sun Yat-sen University | |
| A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer | NCT06363084 | Resectable Panc... | Nimotuzumab | 18 Years - | Ruijin Hospital | |
| Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma | NCT01145170 | Diffuse Intrins... | Radiotherapy Nimotuzumab | 3 Years - 18 Years | Eurofarma Laboratorios S.A. | |
| A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN | NCT04949503 | Locally Advance... | nimotuzumab | 18 Years - | Biotech Pharmaceutical Co., Ltd. | |
| Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer | NCT00702481 | Head and Neck C... | Nimotuzumab Cisplatin Radiation | 21 Years - 70 Years | National Cancer Centre, Singapore | |
| Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients | NCT01393080 | Non-small Cell ... | Nimotuzumab and... TP regimen | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | NCT06429904 | Locally Advance... | Nimotuzumab+ NA... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Nimotuzumab in Children With Intrinsic Pontine Glioma | NCT00561691 | Diffuse Instrin... | nimotuzumab | 3 Years - 20 Years | Oncoscience AG |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
